NIH Resumes Indian Trials, Will Others Follow?
This article was originally published in Scrip
Executive Summary
More than two years after it cut back on Indian clinical trials, the US National Institutes of Health (NIH), the largest public funder of biomedical research in the world, appears to have recommenced activity in the area, albeit on a cautious note.
You may also be interested in...
Industry Sponsored Trials Fall Sharply In Challenging Indian Environment
A rise in bureaucracy and increased liability for clinical trial sponsors have impacted the popularity of India as a location for pharmaceutical companies’ clinical studies. Trialtrove’s Deborah Jeanfavre examines the data, which show a continuing decrease in new industry-sponsored trials starting in India over the past five years.
Sun Flags Up New Prescriptions Drought Amid COVID-19
Sun Pharma says that the first quarter of 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
US Phlow Model And Drug Nationalism: Do Indian Firms Need To Be Watchful?
The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market.
Need a specific report? 1000+ reports available
Buy Reports